Internal and Emergency Medicine (2021) 16:49–60
https://doi.org/10.1007/s11739-020-02525-7

IM - REVIEW

The Refeeding Syndrome: a neglected but potentially serious condition for inpatients. A narrative review

Valentina Ponzo[1] · Marianna Pellegrini[1] · Iolanda Cioffi[2] · Luca Scaglione[3] · Simona Bo[1]

Received: 29 July 2020 / Accepted: 30 September 2020 / Published online: 19 October 2020
© The Author(s) 2020

Abstract

The Refeeding Syndrome (RFS) is a potentially serious, but still overlooked condition, occurring in individuals who are rapidly fed after a period of severe undernourishment. RFS derives from an abnormal electrolyte and fluid shifts leading to many organ dysfunctions. Symptoms generally appear within 2–5 days of re-feeding and may be absent/mild or severe and life threating, depending on the pre-existing degree of malnutrition and comorbidities. The lack of a standard definition and the nonspecificity of the symptoms make both incidence estimate and diagnosis difficult. In 2020, the American Society for Parenteral and Enteral Nutrition (ASPEN) proposed a unifying definition for the RFS and its severity classification. The awareness of the condition is crucial for identifying patients at risk, preventing its occurrence, and improving the management. The objectives of this narrative review were to summarize the current knowledge and recommendations about the RFS and to provide useful tips to help physicians to recognize and prevent the syndrome.

Keywords Hypophosphatemia · Hypokalemia · Hypomagnesemia · Malnutrition · Refeeding syndrome · Thiamine

Introduction

Malnutrition is a frequent and often unrecognized condition among inpatients [1, 2]. Indeed, 20–50% of individuals are at risk of malnutrition or already malnourished at hospital admission, but malnutrition is diagnosed in 7% only [3]. Older age, low socioeconomic status, lack of organizational support, chronic systemic or psychiatric diseases, polytherapy, poor diet, reduced absorption capacity, excessive nutrient losses are the most frequent conditions underlying malnutrition [4]. The management of malnourished inpatients can be difficult due to the risk of metabolic impairment after the start of nutrition [5]. The adverse outcomes of refeeding were firstly reported during the World War II in rapidly re-fed prisoners who had starved for five to six months [6]. People who have fasted for a long time, developed heart, and/or respiratory failure, peripheral edema, neurological symptoms, and death after the introduction of excessive or even appropriate calorie amount [6–8]. In the 80 s, the term 'refeeding syndrome' (RFS) was introduced to describe severe hypophosphatemia and other electrolyte/metabolic abnormalities and the related cardiovascular and pulmonary manifestations leading to death occurring in two chronically malnourished patients who received aggressive dextrose-based parenteral nutrition (PN) [9]. Since then, many cases of RFS have been described as a rare, but severe and potentially fatal complication related to re-feeding (either orally, enterally or parenterally) of individuals who have fasted or consumed very few calories over a long period of time [10, 11]. Among the diseases or conditions predisposing to malnutrition and consequently to RFS after re-feeding, anorexia nervosa [12–14], cancer [15, 16], critical illnesses [13, 17–20], and frailty in the elderly [21–27] are the most frequently implicated.

The switch from a catabolic to an anabolic state may be the cause of the clinical manifestations of the RFS, even though the pathophysiological mechanisms are still not fully

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11739-020-02525-7) contains supplementary material, which is available to authorized users.

✉ Simona Bo
simona.bo@unito.it

[1] Department of Medical Sciences, University of Torino, c.so AM Dogliotti 14, 10126 Turin, Italy

[2] Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy

[3] Internal Medicine Unit, Città della Salute e della Scienza Hospital of Torino, Turin, Italy

understood [28]. Furthermore, the lack of a clear definition accounts for the difficulty of diagnosis and uncertainties in treatment [2, 29]. Therefore, the RFS is a potentially serious condition, often overlooked by many physicians [30]. This is of particular concern because of the high prevalence of hospital malnutrition often underestimated even in the internal medicine wards [31, 32].

The objectives of this narrative review are to summarize the knowledge on the RFS and to focus on the most useful topics for the clinical practice.

Methods

The following databases were queried: PubMed (National Library of Medicine), the Cochrane Library, Excerpta Medica dataBASE (EMBASE), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). The search strategy was performed using the following keywords: refeeding syndrome OR phosphate, potassium, magnesium AND anorexia nervosa, cancer, critically ill patients, elderly. The filters 'humans' and 'adults' were used. Hand searching the references of the identified studies and reviews was carried out too.

Incidence rates for RFS

The lack of a universally recognized RFS definition makes it difficult to obtain precise estimates of its incidence [33]. Indeed, either hypophosphatemia only or multiple electrolyte abnormalities (with different cut offs) with or without clinical manifestations have been considered in its definition [34, 35]. The reported incidence rates ranged between 0 and 80%, depending on the definition and the patient population studied [34]. RFS has been described in 48% of severely malnourished patients, in 34% of intensive care unit (ICU) patients, in 33% of patients with anorexia nervosa (AN), in 25% of cancer inpatients, and in 9.5% of patients hospitalized for malnutrition from gastrointestinal fistulae [10, 12, 33, 36]. Many factors may lead to underestimation of RFS incidence rate, such as insufficient monitoring of the patients' electrolytes after nutrition starting, lack of consultation by experts in clinical nutrition, the nonspecificity of the clinical manifestations of the syndrome in patients with multiple co-morbidity and the physician unawareness [11].

Population at risk for RFS

To identify patients at risk for RFS is necessary evaluating the risk of malnutrition by validated screening tools first, and then assessing the diagnosis and grading the severity of malnutrition [5, 33, 37, 38]. Distinguishing malnutrition from the other related conditions, such as starvation, cachexia, cancer cachexia, and sarcopenia, is important from a clinical point of view (Table 1) [39–44]. The screening for the risk of malnutrition should be performed in inpatients within the first 24–48 h through validated screening tools, such as the Nutritional Risk Screening 2002 (NRS-2002), the Mini Nutritional Assessment-Short Form (MNA-SF), the Malnutrition Universal Screening Tool (MUST), the Short Nutritional Assessment Questionnaire (SNAQ) [5, 37, 39]. If an individual is identified to be at risk of malnutrition, an extensive nutritional assessment for diagnosis and evaluation of the severity of malnutrition should be carried out by an expert in nutrition [39, 40].

A great number of diseases or conditions predisposes to malnutrition [21, 28, 33, 34, 37, 39, 45–47]. These predisposing conditions can be divided into the following categories: predisposing to disease-related malnutrition with inflammation (chronic diseases leading to catabolic inflammatory responses); predisposing to disease-related malnutrition without inflammation (acute disease and injury-related malnutrition); and predisposing to malnutrition in the absence of diseases (hunger, socioeconomic, or psychologic-related conditions, drugs) [39], as summarized in Supplementary Table 1.

In the presence of severe underweight or weight loss, prolonged fasting period, and/or low electrolyte concentrations, the risk of RFS is particularly high [30]. In 2006, the National Institute for Health and Clinical Excellence (NICE) guidelines [48] reported the risk factors to identify people at low or high risk for RSF. In 2018 Friedli et Coll added the very high-risk category [21]. Recently, the American Society for Parenteral and Enteral Nutrition (ASPEN) published updated consensus criteria for identifying adult patients at risk for RFS [33]. These criteria are presented in Table 2.

Diagnosis of RFS

The difficulty in RFS diagnosing is due to the discrepancy between the onset of the symptoms and the occurring of metabolic shift (see below), and the nonspecific nature of its clinical manifestations [46]. There is a great heterogeneity among the published definitions of RFS, ranging from hypophosphatemia alone [18, 19, 22, 24, 27, 49–54] to the presence of severe low-serum electrolyte levels along with fluid balance abnormalities and/or organ dysfunction [16, 21, 34, 55]. Only hypophosphatemia has been universally recognized as a feature of the syndrome [38]. Friedli et Coll. proposed diagnostic criteria for imminent or manifest RFS, based on the electrolyte blood concentrations and clinical symptoms to standardize its prevention and treatment [21]. According to this definition, "imminent" RFS is present

Table 1 Definition of malnutrition and other related conditions

Malnutrition [40]
At least 1 phenotypic criterion and 1 etiologic criterion should be present Phenotypic Criteria: Nonvolitional weight loss Low body mass index Reduced muscle mass Etiologic criteria: Reduced food intake or assimilation Disease burden/inflammation condition
Starvation [44]
Reduction in both fat and fat-free mass due to protein–energy deficiency, which could be reversed solely by the provision of nutrients
Cachexia [42]
Severe weight loss (adults) or growth failure (children) due to loss of muscle ± loss of fat mass associated with increased protein catabolism by underlying chronic illness
Cancer cachexia [41]
A multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment
Sarcopenia [43]
Sarcopenia is a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality.
Sarcopenia is *probable* when low muscle strength is detected (handgrip strength < 27 kg for males and < 16 kg for females). A sarcopenia diagnosis is *confirmed* by the presence of low muscle quantity or quality (ASM/height^2 < 7.0 kg/m^2 for males and < 5.5 kg/m^2 for females). When low muscle strength, low muscle quantity/quality and low physical performance (low gait speed ≤ 0.8 m/s both for males and females) are all detected, sarcopenia is considered severe

BMI body mass index, *ASM* appendicular skeletal muscle mass

when a shift in electrolytes occurs within 72 h after the start of nutritional treatment (i.e., > 30% decrease in blood phosphate from baseline or phosphate values < 0.6 mmol/L or any two other electrolyte shifts below normal range) [21]. "Manifest" RFS is considered if any electrolyte shift occurs in conjunction with typical clinical symptoms (see below) [21].

More recently, the ASPEN proposed diagnostic criteria for distinguishing mild, moderate or severe RFS [33] (Table 3). The extent of the decrease in the serum levels of one or more electrolytes (among phosphate, potassium, or magnesium) defines RFS severity: 10–20% (mild RFS), 20–30% (moderate RFS), > 30% and/or organ dysfunction and/or thiamine deficiency (severe RFS) [33]. Thus, either hypophosphatemia and/or hypokalemia and/or hypomagnesemia qualify the presence of the RFS. The timing of onset is determinant for the diagnosis, since the RFS develops shortly (from hours up to 5 days) after having substantially increased the energy provision to individuals who have been undernourished [33].

Pathophysiology and clinical manifestations

The pathophysiology of the RFS is probably related to the shift from the catabolic to the anabolic metabolic pathways occurring after the re-start of feeding in undernourished subjects. During early starvation, blood glucose and insulin levels decline while glucagon concentrations increase by stimulating glycogenolysis in the liver. When glycogen reserves become depleted, gluconeogenesis is stimulated in the liver, using amino acids derived from muscle breakdown [56]. During prolonged fasting, the body switches to use fats as the main sources of energy with a decrease in basal metabolic rate of 20–25% [57]. Increased lipolysis in fat reserves leads to the production of ketones that are used by the brain as preferred fuel during starvation [29, 56]. During prolonged fasting, several intracellular minerals become severely depleted, particularly phosphate, potassium, and magnesium. However, the concentrations of these minerals may remain within the normal range in the serum because there is a reduction in their renal excretion and because of the phosphate outflow from the cells into the blood, leading to normal blood phosphate levels despite depleted storages [21].

Symptoms generally appear within 2–5 days of re-feeding and may range from absent/mild to a severe and life-threating clinical syndrome, depending on the pre-existing degree of malnutrition and comorbidity [10, 11, 45]. All the body organs may be involved, leading to cardiac, respiratory, hematologic, gastrointestinal, neurologic, and musculoskeletal manifestations, until death [10, 21, 58].

Table 2 Criteria for identifying adult patients at risk for RFS

	NICE [48]		ASPEN 2020 [33]		Friedli 2018 [21]		
	High risk in the presence of		Moderate risk: 2 risk criteria needed	Significant risk: 1 risk criteria needed	Low risk: 1 minor risk factor	High risk: 1 major or 2 minor risk factors	Very high risk
	One or more of the following:	Two or more of the following:			Minor risk factors	Major risk factors	
BMI	< 16 kg/m^2	< 18.5 kg/m^2	16–18.5 kg/m^2	< 16 kg/m^2	< 18.5 kg/m^2	< 16 kg/m^2	< 14 kg/m^2
Weight loss	> 15% within the last 3–6 months	> 10% within the last 3–6 months	5% in 1 month	7.5% in 3 months or > 10% in 6 months	> 10% within the last 3–6 months	> 15% within the last 3–6 months	> 20%
Caloric intake	Little or no nutritional intake > 10 days	Little or no nutritional intake > 5 days	None or negligible oral intake for 5–6 days OR < 75% of estimated energy requirement for > 7 days during an acute illness or injury OR < 75% of estimated energy requirement for > 1 month	None or negligible oral intake for > 7 days OR < 50% of estimated energy requirement for > 5 days during an acute illness or injury OR < 50% of estimated energy requirement for > 1 month	Little or no nutritional intake > 5 days	Little or no nutritional intake > 10 days	Starvation > 15 days
Prefeeding potassium, phosphate, or magnesium serum concentrations	Low levels		Minimally low levels or normal current levels and recent low levels necessitating minimal or single-dose supplementation	Moderately/significantly low levels or minimally low or normal levels and recent low levels necessitating significant or multiple-dose supplementation		Low levels	
Loss of subcutaneous fat			Evidence of moderate loss	Evidence of severe loss			
Loss of muscle mass			Evidence of mild or moderate loss	Evidence of severe loss			
Higher-risk comorbidities*		A history of alcohol abuse or drugs including insulin, chemotherapy, antacids, or diuretics	Moderate disease	Severe disease		A history of alcohol abuse or drugs including insulin, chemotherapy, antacids, or diuretics	

BMI body mass index

*Acquired immunodeficiency syndrome; Advanced neurologic impairment or general inability to communicate needs; Cancer; Chronic alcohol or drug use disorder; Dysphagia and esophageal dysmotility; Eating disorders; Food insecurity and homelessness; Failure to thrive, including physical and sexual abuse and victims of neglect; Hyperemesis gravidarum or protracted vomiting; Major stressors or surgery without nutrition for prolonged periods of time; Malabsorptive states (e.g., short-bowel syndrome, Crohn's disease, cystic fibrosis, pyloric stenosis, maldigestion, pancreatic insufficiency); Postbariatric surgery; Postoperative patients with complications; Prolonged fasting; Protein malnourishment; Refugees

Table 3 Diagnostic criteria for RFS severity [33]

Severity of RFS	Mild	Moderate	Severe
Serum electrolytes*	10–20% less	20–30% less	> 30% less and/or organ dysfunction**
Timing	From hours up to 5 days after increasing the energy provision in an individual at risk		

*Decrease in any (one or more) of electrolyte serum levels, among phosphate, potassium, and/or magnesium

**Resulting from the decrease in any electrolyte and/or from thiamine deficiency

Insulin and carbohydrate metabolism

Rapid refeeding in a starved patient causes the metabolic and hormonal changes underlying the syndrome [59]. The provision of nutrients, above all carbohydrates, increases insulin secretion and promotes a sudden shift from fat to carbohydrates metabolism. Insulin stimulates the sodium potassium ATPase symporter, with magnesium as co-factor, which transports glucose and potassium into the cells and moves out sodium. Moreover, insulin release stimulates anabolic processes that require minerals (promoting cellular uptake of phosphate, potassium, and magnesium) and coenzymes, such as thiamine [29]. The electrolyte shift, along with the depletion of the mineral pool, could lead to profound hypophosphatemia and low extracellular magnesium and potassium concentrations, but not necessarily to the depletion of all together. Furthermore, insulin has an anti-natriuretic effect on renal tubules causing a decrease in urinary sodium and water excretion [59]. This determines a rapid fluid overload that can lead to congestive cardiac failure, arrhythmia, and pulmonary edema.

Hypophosphatemia

The phosphate is predominantly an intracellular mineral that plays a key role in energy production and transfer (as a component of adenosine triphosphate (ATP) [58] and it is necessary for many enzymatic processes of cellular metabolic pathways [60]. During refeeding, the increased phosphate consumption due to enhanced production of phosphorylated intermediates results in reduced generation of ATP and 2,3-diphosphoglycerate with impaired cardiac and respiratory functions, and decreased oxygen release to the tissues (Table 4).

Hypokalemia

Potassium is an intracellular mineral and it is crucial for the maintenance of the sodium–potassium membrane gradient; hypokalemia causes imbalance in the electrochemical membrane potential and impaired transmission of electrical impulses resulting in arrhythmias, cardiac arrest, and neurologic symptoms [61–63].

Hypomagnesemia

Magnesium plays a role as a cofactor for the phosphorylation of ATP and it is important for the maintenance of neuromuscular and enzymatic functions. Its depletion results in increased renal losses of potassium, aggravating hypokalemia with arrhythmias and ECG abnormalities, and in abdominal discomfort and neuromuscular symptoms [64].

Thiamine deficit

Thiamine is another cofactor in ATP production. Its increased consumption during refeeding by the enhanced activity of enzymes implicated in the carbohydrate metabolism may lead to neurologic disorders (dry beriberi, Wernicke encephalopathy and Korsakoff's syndrome), cardiovascular disorders, and metabolic acidosis (due to the conversion of glucose into lactate) [65] (Table 4).

Prevention and treatment

The identification of patients at risk for RFS is the first step to prevent the onset of the syndrome, and to avoid an excessive nutritional replenishment in those individuals [21, 66]. Risk factors should be carefully investigated before starting either oral, enteral, or parenteral nutrition, because every route of calorie administration is implicated in the occurrence of the RFS [33, 58]. Well-trained medical staff and specialized nutritional support teams, consisting of physicians, dieticians, nurses, and pharmacists, positively impact on the patient outcomes [48]. However, a multidisciplinary team is not available in all hospital settings, and often the evaluation of the risk for RFS is left to the clinician's critical sense at the time of starting nutritional support [11, 33, 36, 38, 67]. After defining the degree of RFS risk, the rate of fluid and nutrition administration, the correction of electrolyte imbalances, and the supplementation of vitamins and micronutrients (zinc, iron, selenium) can be determined [36] (Table 5). If a prolonged nutritional support is required,

Table 4 Physiopathology and main clinical features of the RFS

Pathophysiological mechanisms	Clinical manifestations
Hypophosphatemia	
Increased phosphate consumption due to enhanced production of phosphorylated intermediates for glycolysis, the Krebs cycle, and the electron transport chain to produce adenosine triphosphate and 2,3-diphosphoglycerate	Impaired cardiac and respiratory functions (i.e., tachycardia and tachypnea)
	Neurologic symptoms (i.e., confusion, somnolence, lethargy, coma, paresthesia, seizures)
	Hematologic disorders (i.e., hemolysis, dysfunction of platelets and leukocytes, thrombocytopenia)
	Hypoxia (due to impaired oxygen release from 2,3- diphosphoglycerate)
	Muscular disorders (i.e., weakness, rhabdomyolysis, decreased cardiac contractility, myalgia)
Hypokalemia	
Intracellular shift of potassium by insulin stimulation of the Na + /K + ATPase	Cardiac arrhythmias
Impairment of potassium reuptake in the nephron (role of hypomagnesemia)	Neurologic symptoms (i.e., weakness, hyporeflexia, respiratory depression, and paralysis) due to impaired transmission of electrical impulses
Hypomagnesemia	
Not completely clear	Increased renal losses of potassium
Intracellular shift of magnesium after carbohydrate feeding	Cardiac arrhythmias (i.e., torsade de pointes, atrial fibrillation, ventricular arrhythmias)
	Electrocardiograph changes (i.e., prolonged QT and PR, widened QRS)
	Abdominal discomfort (i.e., anorexia, diarrhea, nausea, vomiting)
	Neuromuscular symptoms (i.e., tremor, paraesthesia, tetany, seizures, irritability, confusion, weakness, ataxia)
Thiamine deficiency	
Increased consumption of thiamine by glucose metabolism enzymes	Neurologic disorders or dry beriberi, Wernicke encephalopathy and Korsakoff's syndrome (i.e., ataxia, disturbance of consciousness, oculomotor abnormalities, symptoms of acute peripheral neuropathy, coma)
	Cardiovascular disorders or wet beriberi (i.e., peripheral edema, heart failure)
	Metabolic acidosis (due to glucose conversion to lactate)
Sodium and fluid retention	
Renal sodium and fluid retention due to insulin antinatriuretic properties (after carbohydrate feeding)	Peripheral edema
	Pulmonary edema and heart failure (due to increased vasoconstriction and peripheral resistance by sodium stimulation of noradrenaline and angiotensin II)
Hyperglycemia	
Increased tissue resistance to endogenous glucose	Metabolic acidosis
	Hypercapnia, respiratory failure, and risk of fatty liver due to lipogenesis (stimulated by insulin)

ATP adenosine triphosphate

adjustments over time in accordance with the patient clinical conditions might be necessary [58].

Several therapeutic approaches have been proposed to prevent or treat the RSF [10, 21, 28, 36, 45, 46, 48, 67, 68] (Fig. 1). Since hypophosphatemia occurs after refeeding, according to the grade of RSF risk, phosphate may be administered preventively before the initiation of nutritional therapy, even if blood levels are in the low-normal range [21]. Similarly, thiamine is essential in carbohydrates metabolism and should be supplemented before restart feeding even in the case of normal blood levels [21]. An excessive administration of glucose by stimulating insulin production leads to the consumption of electrolytes (mainly phosphate) through the anabolic pathways. Starting re-feeding very gradually, independently of the route of administration, is therefore mandatory [58]. Owing to the risk of fluid overload, sodium and hydration should be provided cautiously, until the patient is metabolically stable [38]. In

Table 5 Prevention and treatment of the RFS according to the risk [21, 36, 38]

Day	Treatment	Low risk	High risk	Very high risk	Monitoring
1	Thiamine	200–300 mg	200–300 mg	200–300 mg	Body weight Vital signs Clin Exam Lab tests§
	Multivitamin*	Yes	Yes	Yes	
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	25–30 ml/kg/day	20–25 ml/kg/day	
	Nutritional support**	15–25 kcal/kg/day	10–15 kcal/kg/day	5–10 kcal/kg/day	
2	Thiamine	200–300 mg	200–300 mg	200–300 mg	Body weight Vital signs Clin Exam Lab tests§
	Multivitamin*	Yes	Yes	Yes	
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	25–30 ml/kg/day	20–25 ml/kg/day	
	Nutritional support**	15–25 kcal/kg/day	10–15 kcal/kg/day	5–10 kcal/kg/day	
3	Thiamine	200–300 mg	200–300 mg	200–300 mg	Body weight Vital signs Clin Exam Lab tests§
	Multivitamin*	Yes	Yes	Yes	
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	25–30 ml/kg/day	20–25 ml/kg/day	
	Nutritional support**	15–25 kcal/kg/day	10–15 kcal/kg/day	5–10 kcal/kg/day	
4	Thiamine	No	No	200–300 mg	Vital signs Clin Exam
	Multivitamin*	Yes	Yes	Yes	
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	25–30 ml/kg/day	
	Nutritional support**	30 kcal/kg/day	15–25 kcal/kg/day	10–20 kcal/kg/day	
5	Thiamine	No	No	200–300 mg	Body weight Vital signs Clin Exam Lab tests§
	Multivitamin*	Yes	Yes	Yes	
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	25–30 ml/kg/day	
	Nutritional support**	full requirements	15–25 kcal/kg/day	10–20 kcal/kg/day	
6	Multivitamin*	Yes	Yes	Yes	Vital signs Clin Exam
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	25–30 ml/kg/day	
	Nutritional support**	full requirements	25–30 kcal/kg/day	10–20 kcal/kg/day	
7	Multivitamin*	Yes	Yes	Yes	Vital signs Clin Exam
	Sodium restriction	No	< 1 mmol/kg/day	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	30–35 ml/kg/day	
	Nutritional support**	full requirements	full requirements	20–30 kcal/kg/day	
8	Multivitamin*	Yes	Yes	Yes	Vital signs Clin Exam
	Sodium restriction	No	No	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	30–35 ml/kg/day	
	Nutritional support**	full requirements	full requirements	20–30 kcal/kg/day	
9	Multivitamin*	Yes	Yes	Yes	Body weight Vital signs Clin Exam Lab tests§
	Sodium restriction	No	No	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	30–35 ml/kg/day	
	Nutritional support**	Full requirements	Full requirements	20–30 kcal/kg/day	
10	Multivitamin*	Yes	Yes	Yes	Vital signs Clin Exam
	Sodium restriction	No	No	< 1 mmol/kg/day	
	Fluids	30–35 ml/kg/day	30–35 ml/kg/day	30–35 ml/kg/day	
	Nutritional support**	Full requirements	Full requirements	Full requirements	

Clin Exam clinical examination

*Vitamins should be supplemented to 200% and the trace elements to 100% of the recommended daily intakes; replace electrolyte according to the electrolyte serum levels and RFS severity: 1–1.5 mmol/Kg/day potassium, 0.2–0.4 mmol/Kg/day magnesium, 0.3–0.6 mmol/Kg/day phosphate

**Provide 15–20% proteins, 30–40% carbohydrates, 40–60% fats

§Laboratory tests include phosphate, sodium, potassium, magnesium, calcium, glucose, creatinine, urea



Fig. 1 Practical tips for the prevention and approach to the RFS

case of overt symptoms, energy and fluid intakes should be reduced and adapted to the clinical conditions [30].

Specific conditions might require special attention.

Anorexia nervosa

Most inpatients with AN are at high risk for RFS [12]; refeeding is the first step of the treatment and must be managed very cautiously [66, 69]. International guidelines are based mainly on clinical experience, due to the lack of well-designed trials in inpatients with AN [70, 71]. At hospital admission, the recommended calorie provision ranges from 5–20 kcal/kg to 30–40 kcal/kg [70, 71]. A progressive increase of 5–10 kcal/kg/day (if high risk of RFS) or 10–20 kcal/kg/day (if moderate risk of RFS) could be carried out after the stabilization of the clinical conditions (e.g., improvement of electrocardiographic abnormalities, correction of electrolyte imbalance, replacement of thiamine and vitamins, and stabilization of comorbidities) [48, 66, 72]. Caloric provision could increase up to 70–100 kcal/kg per day if patients have increased energy requirement such as in case of inappropriate behaviors (throwing or hiding food, vomiting, intense exercise, etc.) [71]. Refeeding with a lower calorie provision and a slow energy increase may be a better approach for severely malnourished patients with chronic comorbidity, while higher caloric intakes might be reserved for moderately malnourished patients with acute illnesses [69]. Preventive supplementation with phosphate, potassium, magnesium, thiamine and other vitamins, trace elements, and minerals as well as sodium and fluid restriction are recommended too [66, 71]. Both meal-based approaches (with or without oral nutritional supplements) and combined approaches with nasogastric feeding can be used in inpatients requiring higher caloric intakes [69, 73]. Parenteral nutrition is not recommended unless no other form of refeeding is possible [69].

Cancer

Up to 50–80% of patients with advanced cancer are at high risk of developing RFS [74], in particular individuals with head and neck cancer [75, 76]. Cancer cachexia cannot be arrested or reversed by any known form of nutritional, hormonal, or pharmacological treatment [77]. There are no specific guidelines on how to re-feed cancer patients at risk for RFS, being NICE recommendations [48] the most frequently used [29, 75, 76, 78, 79]. In patients eating little or nothing for more than 5 days, refeeding should be started with no more than 50% of the caloric requirements, with ≤ 10 kcal/kg/day in high-risk patients and ≤ 5 kcal/kg/day in very high-risk patients (BMI < 14 kg/m^2 or negligible intake for 2 weeks or more) [48]. Owing to the potential benefit of protein intake on muscle anabolism, cancer patients should receive a protein intake of 1 g/kg/day up to 1.5 g/kg/day [79]. When oral refeeding is possible, the use of oral nutritional supplements can be useful in reaching nutritional goals [76]; if oral feeding is either impossible or insufficient, enteral, or parenteral nutrition should be considered [76], with slow progressive caloric increase to reach the full needs within 4–7 days [74]. In the case of cancer cachexia, a very cautious refeeding should begin by initially supplying about 25% of the estimated calorie requirement [77], with a very gradual caloric increase over several days, and a careful monitoring of phosphate and electrolytes serum levels [80].

Conclusions

This narrative review provides the latest information on the management of RFS in light of the current evidence. Although RFS is a frequent condition that can have serious consequences above all in specific categories of inpatients, it is often undiagnosed and overlooked by physicians. Its knowledge is essential to avoid rapid and excessive nourishing of at-risk patients; thus, preventing serious complications, long hospital stays, and the increase in health costs.

Author contribution All authors contributed to the study conception and design. Idea for the article: SB. Writing—original draft preparation MP; Writing—review and editing: VP, IC, LS; Supervision: LS, SB. All authors read and approved the final manuscript.

Funding Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. The authors did not receive financial support for the research, authorship, and/or publication of this article.

Data availability Not applicable.

Code availability Not applicable.

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Statement of human and animal rights This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent For this type of study, formal consent is not required.

Consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Vest MT, Papas MA, Shapero M, McGraw P, Capizzi A, Jurkovitz C (2018) Characteristics and outcomes of adult inpatients with malnutrition. J Parenter Enteral Nutr 42:1009–1016. https://doi.org/10.1002/jpen.1042
2. Janssen G, Pourhassan M, Lenzen-Großimlinghaus R, Jäger M, Schäfer R, Spamer C, Cuvelier I, Volkert D, Wirth R (2019) The refeeding syndrome revisited: you can only diagnose what you know. Eur J Clin Nutr 73:1458–1463. https://doi.org/10.1038/s41430-019-0441-x
3. Lanctin DP, Merced-Nieves F, Mallett RM, Arensberg MB, Guenter P, Sulo S, Platts-Mills TF (2019) Prevalence and economic burden of malnutrition diagnosis among patients presenting to united states emergency departments. Acad Emerg Med. https://doi.org/10.1111/acem.13887
4. Barker LA, Gout BS, Crowe TC (2011) Hospital malnutrition: prevalence, identification and impact on patients and the healthcare system. Int J Environ Res Public Health 8:514–527. https://doi.org/10.3390/ijerph8020514
5. Reber E, Gomes F, Bally L, Schuetz P, Stanga Z (2019) Nutritional management of medical inpatients. J Clin Med 8:1130. https://doi.org/10.3390/jcm8081130
6. Schnitker MA, Mattman PE, Bliss TL (1951) A clinical study of malnutrition in Japanese prisoners of war. Ann Intern Med 35:69–96. https://doi.org/10.7326/0003-4819-35-1-69
7. Keys A, Brožek J, Henschel A, Mickelsen O, Taylor HL (1950) The biology of human starvation, Vols. 1 & 2
8. Netherlands, Committee on Malnutrition, Burger GCE, Drummond JC, Sandstead HR (1948) Malnutrition and starvation in Western Netherlands: September 1944–July 1945 Pt. 1. General State Print. Office, The Hague

9. Weinsier RL, Krumdieck CL (1981) Death resulting from overzealous total parenteral nutrition: the refeeding syndrome revisited. Am J Clin Nutr 34:393–399. https://doi.org/10.1093/ajcn/34.3.393
10. Boateng AA, Sriram K, Meguid MM, Crook M (2010) Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition 26:156–167. https://doi.org/10.1016/j.nut.2009.11.017
11. Skipper A (2012) Refeeding syndrome or refeeding hypophosphatemia: a systematic review of cases. Nutr Clin Pract 27:34–40. https://doi.org/10.1177/0884533611427916
12. Brown CA, Sabel AL, Gaudiani JL, Mehler PS (2015) Predictors of hypophosphatemia during refeeding of patients with severe anorexia nervosa. Int J Eat Disord 48:898–904. https://doi.org/10.1002/eat.22406
13. Vignaud M, Constantin J-M, Ruivard M, Villemeyre-Plane M, Futier E, Bazin J-E, Annane D, AZUREA group (AnorexieRea Study Group) (2010) Refeeding syndrome influences outcome of anorexia nervosa patients in intensive care unit: an observational study. Crit Care 14:R172. https://doi.org/10.1186/cc9274
14. Yamazaki T, Inada S, Yoshiuchi K (2019) Body mass index cut-off point associated with refeeding hypophosphatemia in adults with eating disorders. Int J Eat Disord 52:1322–1325. https://doi.org/10.1002/eat.23177
15. Grasso S, Ferro Y, Migliaccio V et al (2013) Hypokalemia during the early phase of refeeding in patients with cancer. Clinics 68:1413–1415. https://doi.org/10.6061/clinics/2013(11)05
16. Rasmussen SO, Kristensen MB, Wessel I, Andersen JR (2016) Incidence and risk factors of refeeding syndrome in head and neck cancer patients-an observational study. Nutr Cancer 68:1320–1329. https://doi.org/10.1080/01635581.2016.1225103
17. Marik PE, Bedigian MK (1996) Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study. Arch Surg 131:1043–1047. https://doi.org/10.1001/archsurg.1996.01430220037007
18. Doig GS, Simpson F, Heighes PT, Bellomo R, Chesher D, Caterson ID, Reade MC, Harrigan PWJ, Refeeding Syndrome Trial Investigators Group (2015) Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial. Lancet Respir Med 3:943–952. https://doi.org/10.1016/S2213-2600(15)00418-X
19. Fuentes E, Yeh DD, Quraishi SA et al (2017) hypophosphatemia in enterally fed patients in the surgical intensive care unit: common but unrelated to timing of initiation or aggressiveness of nutrition delivery. Nutr Clin Pract 32:252–257. https://doi.org/10.1177/0884533616662988
20. Olthof LE, Koekkoek WACK, van Setten C, Kars JCN, van Blokland D, van Zanten ARH (2018) Impact of caloric intake in critically ill patients with, and without, refeeding syndrome: a retrospective study. Clin Nutr 37:1609–1617. https://doi.org/10.1016/j.clnu.2017.08.001
21. Friedli N, Stanga Z, Culkin A, Crook M, Laviano A, Sobotka L, Kressig RW, Kondrup J, Mueller B, Schuetz P (2018) Management and prevention of refeeding syndrome in medical inpatients: an evidence-based and consensus-supported algorithm. Nutrition 47:13–20. https://doi.org/10.1016/j.nut.2017.09.007
22. Dror Y, Almashanu S, Lubart E, Sela B-A, Shimoni L, Segal R (2013) The impact of refeeding on blood fatty acids and amino acid profiles in elderly patients: a metabolomic analysis. JPEN J Parenter Enteral Nutr 37:109–116. https://doi.org/10.1177/0148607112443260
23. Gaudiani JL, Sabel AL, Mascolo M, Mehler PS (2012) Severe anorexia nervosa: outcomes from a medical stabilization unit. Int J Eat Disord 45:85–92. https://doi.org/10.1002/eat.20889
24. Gaudiani JL, Brinton JT, Sabel AL, Rylander M, Catanach B, Mehler PS (2016) Medical outcomes for adults hospitalized with severe anorexia nervosa: an analysis by age group. Int J Eat Disord 49:378–385. https://doi.org/10.1002/eat.22437
25. Henderson S, Boyce F, Sumukadas D, Witham MD (2010) Changes in serum magnesium and phosphate in older hospitalised patients–correlation with muscle strength and risk factors for refeeding syndrome. J Nutr Health Aging 14:872–876. https://doi.org/10.1007/s12603-010-0261-0
26. Kagansky N, Levy S, Koren-Morag N, Berger D, Knobler H (2005) Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival. J Intern Med 257:461–468. https://doi.org/10.1111/j.1365-2796.2005.01457.x
27. Lubart E, Leibovitz A, Dror Y, Katz E, Segal R (2009) Mortality after nasogastric tube feeding initiation in long-term care elderly with oropharyngeal dysphagia–the contribution of refeeding syndrome. Gerontology 55:393–397. https://doi.org/10.1159/000218162
28. Stanga Z, Brunner A, Leuenberger M, Grimble RF, Shenkin A, Allison SP, Lobo DN (2008) Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr 62:687–694. https://doi.org/10.1038/sj.ejcn.1602854
29. Mehanna HM, Moledina J, Travis J (2008) Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 336:1495–1498. https://doi.org/10.1136/bmj.a301
30. Friedli N, Odermatt J, Reber E, Schuetz P, Stanga Z (2020) Refeeding syndrome: update and clinical advice for prevention, diagnosis and treatment. Curr Opin Gastroenterol 36:136–140. https://doi.org/10.1097/MOG.0000000000000605
31. Rinninella E, Cintoni M, De Lorenzo A, Addolorato G, Vassallo G, Moroni R, Miggiano GAD, Gasbarrini A, Mele MC (2018) Risk, prevalence, and impact of hospital malnutrition in a tertiary care referral university hospital: a cross-sectional study. Intern Emerg Med 13:689–697. https://doi.org/10.1007/s11739-018-1884-0
32. Finocchiaro C, Fanni G, Bo S (2019) Clinical impact of hospital malnutrition. Intern Emerg Med 14:7–9. https://doi.org/10.1007/s11739-018-1987-7
33. da Silva JSV, Seres D, Sabino K et al (2020) ASPEN Consensus recommendations for refeeding syndrome. Nutr Clin Pract 35(2):178–195. https://doi.org/10.1002/ncp.10474
34. Friedli N, Stanga Z, Sobotka L, Culkin A, Kondrup J, Laviano A, Mueller B, Schuetz P (2017) Revisiting the refeeding syndrome: results of a systematic review. Nutrition 35:151–160. https://doi.org/10.1016/j.nut.2016.05.016
35. Khan LUR, Ahmed J, Khan S, MacFie J (2011) Refeeding syndrome: a literature review. Gastroenterol Res Pract. https://doi.org/10.1155/2011/410971
36. McKnight CL, Newberry C, Sarav M, Martindale R, Hurt R, Daley B (2019) Refeeding syndrome in the critically ill: a literature review and clinician's guide. Curr Gastroenterol Rep 21:58. https://doi.org/10.1007/s11894-019-0724-3
37. Pourhassan M, Cuvelier I, Gehrke I, Marburger C, Modreker MK, Volkert D, Willschrei H-P, Wirth R (2018) Risk factors of refeeding syndrome in malnourished older hospitalized patients. Clin Nutr 37:1354–1359. https://doi.org/10.1016/j.clnu.2017.06.008
38. Reber E, Friedli N, Vasiloglou MF, Schuetz P, Stanga Z (2019) Management of refeeding syndrome in medical inpatients. J Clin Med 8:2202. https://doi.org/10.3390/jcm8122202
39. Cederholm T, Barazzoni R, Austin P et al (2017) ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 36:49–64. https://doi.org/10.1016/j.clnu.2016.09.004
40. Cederholm T, Jensen GL, Correia MITD et al (2019) GLIM criteria for the diagnosis of malnutrition – A consensus report

from the global clinical nutrition community. Clin Nutr 38:1–9. https://doi.org/10.1016/j.clnu.2018.08.002
41. Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
42. Evans WJ, Morley JE, Argilés J et al (2008) Cachexia: a new definition. Clin Nutr 27:793–799. https://doi.org/10.1016/j.clnu.2008.06.013
43. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169
44. Thomas DR (2007) Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 26:389–399. https://doi.org/10.1016/j.clnu.2007.03.008
45. Walmsley RS (2013) Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition. J Gastroenterol Hepatol 28(Suppl 4):113–117. https://doi.org/10.1111/jgh.12345
46. Pulcini CD, Zettle S, Srinath A (2016) Refeeding syndrome. Pediatr Rev 37:516–523. https://doi.org/10.1542/pir.2015-0152
47. Michalsen A, Li C (2013) Fasting therapy for treating and preventing disease—current state of evidence. Forsch Komplementmed 20:444–453. https://doi.org/10.1159/000357765
48. Guidance | Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | Guidance | NICE. https://www.nice.org.uk/guidance/cg32/chapter/1-Guidance#screening-for-malnutrition-and-the-risk-of-malnutrition-in-hospital-and-the-community. Accessed 2 Jun 2020
49. Marvin VA, Brown D, Portlock J, Livingstone C (2008) Factors contributing to the development of hypophosphataemia when refeeding using parenteral nutrition. Pharm World Sci 30:329–335. https://doi.org/10.1007/s11096-007-9180-5
50. Elnenaei MO, Alaghband-Zadeh J, Sherwood R, Awara MA, Moniz C, le Roux CW (2011) Leptin and insulin growth factor 1: diagnostic markers of the refeeding syndrome and mortality. Br J Nutr 106:906–912. https://doi.org/10.1017/S0007114511001097
51. Rigaud D, Tallonneau I, Brindisi M-C, Vergès B (2012) Prognosis in 41 severely malnourished anorexia nervosa patients. Clin Nutr 31:693–698. https://doi.org/10.1016/j.clnu.2012.02.016
52. Chen L-J, Chen H-L, Bair M-J, Wu C-H, Lin I-T, Lee Y-K, Chu C-H (2014) Refeeding syndrome in Southeastern Taiwan: our experience with 11 cases. World J Gastroenterol 20:10525–10530. https://doi.org/10.3748/wjg.v20.i30.10525
53. Kraaijenbrink BVC, Lambers WM, Mathus-Vliegen EMH, Siegert CEH (2016) Incidence of refeeding syndrome in internal medicine patients. Neth J Med 74:116–121
54. Pantoja F, Fragkos KC, Patel PS, Keane N, Samaan MA, Barnova I, Di Caro S, Mehta SJ, Rahman F (2019) Refeeding syndrome in adults receiving total parenteral nutrition: an audit of practice at a tertiary UK centre. Clin Nutr 38:1457–1463. https://doi.org/10.1016/j.clnu.2018.06.967
55. Rio A, Whelan K, Goff L, Reidlinger DP, Smeeton N (2013) Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study. BMJ Open 3:e002173. https://doi.org/10.1136/bmjopen-2012-002173
56. Mehanna H, Nankivell PC, Moledina J, Travis J (2009) Refeeding syndrome—awareness, prevention and management. Head Neck Oncol 1:4. https://doi.org/10.1186/1758-3284-1-4
57. McCray S, Walker S, Parrish CR (2005) Much ado about refeeding. Pract Gastroenterol 28:26–44
58. Crook MA, Hally V, Panteli JV (2001) The importance of the refeeding syndrome. Nutrition 17:632–637. https://doi.org/10.1016/s0899-9007(01)00542-1
59. Hearing SD (2004) Refeeding syndrome. BMJ 328:908–909. https://doi.org/10.1136/bmj.328.7445
60. Weisinger JR, Bellorín-Font E (1998) Magnesium and phosphorus. Lancet 352:391–396
61. McDonough AA, Youn JH (2017) Potassium homeostasis: the knowns, the unknowns, and the health benefits. Physiology (Bethesda) 32:100–111. https://doi.org/10.1152/physiol.00022.2016
62. Elliott TL, Braun M (2017) Electrolytes: potassium disorders. FP Essent 459:21–28
63. Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A (2018) Hypokalemia: a clinical update. Endocr Connect 7:R135–R146. https://doi.org/10.1530/EC-18-0109
64. Ahmed F, Mohammed A (2019) Magnesium: the forgotten electrolyte-a review on hypomagnesemia. Med Sci (Basel). https://doi.org/10.3390/medsci7040056
65. Polegato BF, Pereira AG, Azevedo PS, Costa NA, Zornoff LAM, Paiva SAR, Minicucci MF (2019) Role of thiamine in health and disease. Nutr Clin Pract 34:558–564. https://doi.org/10.1002/ncp.10234
66. Skowrońska A, Sójta K, Strzelecki D (2019) Refeeding syndrome as treatment complication of anorexia nervosa. Psychiatr Pol 53:1113–1123. https://doi.org/10.12740/PP/OnlineFirst/90275
67. Aubry E, Friedli N, Schuetz P, Stanga Z (2018) Refeeding syndrome in the frail elderly population: prevention, diagnosis and management. Clin Exp Gastroenterol 11:255–264. https://doi.org/10.2147/CEG.S136429
68. Kraft MD, Btaiche IF, Sacks GS (2005) Review of the refeeding syndrome. Nutr Clin Prac 20:625–633. https://doi.org/10.1177/0115426505020006625
69. Garber AK, Sawyer SM, Golden NH, Guarda AS, Katzman DK, Kohn MR, Le Grange D, Madden S, Whitelaw M, Redgrave GW (2016) A systematic review of approaches to refeeding hospitalized patients with anorexia nervosa. Int J Eat Disord 49:293–310. https://doi.org/10.1002/eat.22482
70. Resmark G, Herpertz S, Herpertz-Dahlmann B, Zeeck A (2019) Treatment of anorexia nervosa-new evidence-based guidelines. J Clin Med. https://doi.org/10.3390/jcm8020153
71. Cuerda C, Vasiloglou MF, Arhip L (2019) Nutritional management and outcomes in malnourished medical inpatients: anorexia nervosa. J Clin Med. https://doi.org/10.3390/jcm8071042
72. Robinson P, Rhys Jones W (2018) MARSIPAN: management of really sick patients with anorexia nervosa. BJPsych Advances 24:20–32. https://doi.org/10.1192/bja.2017.2
73. Rizzo SM, Douglas JW, Lawrence JC (2019) Enteral nutrition via nasogastric tube for refeeding patients with anorexia nervosa: a systematic review. Nutr Clin Pract 34:359–370. https://doi.org/10.1002/ncp.10187
74. Szeja N, Grosicki S (2020) Refeeding syndrome in hematological cancer patients - current approach. Expert Rev Hematol 13:201–212. https://doi.org/10.1080/17474086.2020.1727738
75. Windpessl M, Mayrbaeurl B, Baldinger C, Tiefenthaller G, Prischl FC, Wallner M, Thaler J (2017) Refeeding syndrome in oncology: report of four cases. World J Oncol 8:25–29. https://doi.org/10.14740/wjon1007w
76. Kaderbay A, Atallah I, Fontaine E, Chobert-Bakouline M, Schmitt S, Mitariu P, Righini CA (2018) Malnutrition and refeeding syndrome prevention in head and neck cancer patients: from theory to clinical application. Eur Arch Otorhinolaryngol 275:1049–1058. https://doi.org/10.1007/s00405-018-4935-2
77. Palesty JA, Dudrick SJ (2011) Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks. Surg Clin North Am 91:653–673. https://doi.org/10.1016/j.suc.2011.02.007
78. Ahmed S, Travis J, Mehanna H (2011) Re-feeding syndrome in head and neck—prevention and management. Oral Oncol 47:792–796. https://doi.org/10.1016/j.oraloncology.2010.06.009

79. Arends J, Bachmann P, Baracos V et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11–48. https://doi.org/10.1016/j.clnu.2016.07.015
80. Arends J, Baracos V, Bertz H et al (2017) ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 36:1187–1196. https://doi.org/10.1016/j.clnu.2017.06.017

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.